JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: Dual targeting BCR-ABL and JAK2 activities in CML stem/progenitor cells may consequently lead to more effective disease eradication, especially in patients at high risk of TKI resistance and disease progression.